Energy Sensing
Early studies examine AMPK, a pathway that senses energy available to cells. It also helps coordinate metabolic responses.
Explore mitochondrial and metabolic research with individualized medical guidance.
Book Your Appointment
MOTS-c is a peptide containing 16 amino acids. It comes from mitochondrial DNA. Scientists study its role in cell-energy signals and responses to metabolic stress.

Emerging research: MOTS-c is investigational and not FDA-approved. Naturally occurring signaling and experimental treatment are different questions; clinical benefits and long-term safety remain uncertain.
Mitochondria produce energy and communicate with the rest of the cell. MOTS-c research explores how those signals relate to changing energy demands.


Early studies examine AMPK, a pathway that senses energy available to cells. It also helps coordinate metabolic responses.
Research explores communication between mitochondria and the nucleus during metabolic stress. However, these mechanisms alone do not establish a treatment for patients.
The science spans laboratory models, animal experiments, and human observations. Each type of evidence answers a different question.
Experimental work examines glucose use and insulin-sensitivity pathways. It does not establish MOTS-c as a treatment for diabetes or a substitute for prescribed care.
Human studies have measured natural MOTS-c levels around exercise. However, this does not show that taking it reproduces the benefits of physical activity.
Researchers explore how cells adapt to different fuel sources and energy demands. Do not assume these findings mean better energy or weight outcomes in patients.
Mitochondrial function changes with age, making these signals a research interest. Research has not established that it reverses aging or extends human life.
The MOTS-MET study record describes a Phase 2a, placebo-controlled trial in adults with prediabetes and overweight or obesity.


The record describes assessments of insulin sensitivity and safety. No results were posted when reviewed on September 9, 2026. Registration does not mean FDA approval or confirmation that the intervention works.
Research has not established repeated-use safety, interactions, or a validated clinical regimen.


FDA has raised concerns about peptide clumping, impurities, product identity, and possible immune reactions.
Injection can cause local reactions or infection. Researchers also need to study metabolic effects and interactions with glucose-lowering drugs. Do not assume they work safely together.
Discuss medications, pregnancy or breastfeeding, and significant medical conditions with your provider. Limited data cannot establish safety for these groups.
Adding MOTS-c to other peptides or metabolic medications does not establish extra benefit. Combination safety and effective dosing remain uncertain.
Clear information about the product, evidence, and regulatory status belongs in every treatment discussion.
Compounding advisory review is separate from drug approval. A committee discussion or recommendation does not itself establish final list inclusion or availability.
Any prescribing or compounding must satisfy current requirements. Pharmacy licensure and purity testing do not establish permission to compound an ingredient or prove clinical benefit.
Compounded medicines are not FDA-approved. This page does not promise a MOTS-c prescription or a future availability date.
If you are concerned about fatigue, weight, or blood glucose, begin with an evaluation of your symptoms and health history.
Review sleep, activity, nutrition, medications, and relevant medical conditions. Your provider chooses tests based on your individual needs.
Our Pasadena team can discuss established care options and your research questions. Together, you can plan appropriate follow-up.


Practical answers about the research and your care options.


No. MOTS-c remains investigational. Research registration or compounding review does not establish drug approval.
Research has not established clinical benefits. Early findings and a registered trial cannot replace completed human results.
No evidence establishes MOTS-c administration as a replacement for physical activity. Exercise-related changes in natural peptide levels answer a different scientific question.
Research has not established a validated clinical regimen. A research protocol is not a guide to treating yourself.
MOTS-c is prohibited at all times under WADA rules. Athletes should consult their anti-doping organization before using any medication, peptide, or supplement.
Researchers do not adequately understand interactions. Review all medicines and supplements with your clinician. Do not change prescribed treatment to add an investigational compound.
The full range of side effects remains unclear. Concerns include product impurities, immune reactions, injection risks, and unintended metabolic effects.
A review of your concerns, health history, research questions, and appropriate care options. A consultation does not guarantee access to MOTS-c.
Meet with our medical team to discuss your concerns and build a personalized care plan.
Book Your AppointmentMOTS-c is investigational and not FDA-approved. This page is educational and does not establish treatment availability or replace medical advice. Human benefits and long-term safety remain uncertain.
Clinical, regulatory, and research sources. Laboratory findings and study registration do not establish treatment outcomes.